In essence, sTREM2, MCP-1, IL-6, TGF-β, and, particularly, YKL-40 are interesting novel inflammatory CSF biomarkers, but they cannot be proposed in detecting the early asymptomatic phases of AD, as it would be altered with disease-modifying treatments. Here, TGFB1 is linked to Alzheimer disease.